Medication Therapy Management in 2026: A Practical Guide to Eligibility, Documentation, and Follow-Up

Answer first: medication therapy management (MTM) is most useful in a community pharmacy when eligibility, outreach, clinical review, documentation, communication, and follow-up are designed as one workflow. A completed medication review is not the endpoint. The service should produce an understandable patient plan, a defined next action, and a reliable way to close the loop with the patient and prescriber when needed.

This article provides operational education, not individualized medical, legal, or billing advice. Medicare Part D plan rules, payer requirements, state scope, and collaborative-practice arrangements can differ. Verify current requirements before billing or representing that a patient is eligible for a particular benefit.

Contents

• Eligibility and referral
• Conducting a useful review
• Documentation and communication
• Follow-up workflow
• Checklist
• FAQ

Key takeaways

• Confirm the payer or program pathway before telling a patient that MTM is covered.
• Use a structured medication and care-goal review, not a generic conversation.
• Document what was identified, what was discussed, the action owner, and the follow-up deadline.
• Escalate clinical issues to the appropriate prescriber or care setting rather than trying to solve work outside the pharmacy’s authority.

Begin with eligibility, access, and a clear invitation

MTM can refer to different services across Medicare Part D, other payer programs, health systems, and pharmacy-led clinical models. CMS requires Part D sponsors to offer an MTM program that meets statutory and regulatory requirements, but an individual patient’s eligibility, offered services, and delivery method depend on the plan. A pharmacy should use the current plan or contracted-program information rather than assuming that a patient with multiple medicines qualifies.

Build an intake process that identifies the source of the referral, program eligibility status, preferred language and contact method, caregiver involvement where authorized, medication sources, and the reason for the review. Offer accessible appointment options and explain what the patient should bring: prescription and nonprescription products, supplements, device questions, recent discharge information when relevant, and the names of other clinicians. Do not require a patient to reconstruct the medication list from memory if the pharmacy can prepare a preliminary list from available records.

An invitation should be accurate and plain. Explain the service, expected length, possible cost if known, privacy boundaries, and what will happen after the appointment. Avoid promising that every medication problem will be resolved in one encounter. Patients are more likely to participate when the purpose is concrete: understanding a regimen, reducing confusion after a change, preparing questions for a prescriber, or finding a safe path for a documented barrier.

Make the review clinically useful and operationally realistic

Start by reconciling what the patient reports taking with the information available to the pharmacy. Ask about indication in the patient’s own words, dose, timing, missed doses, side effects or concerns, access barriers, monitoring questions, and goals. A medication list can be technically complete yet clinically misleading if it does not show what the patient actually uses.

Use a consistent review structure so staff can prepare the record and the pharmacist can focus on judgment. Group questions by medication purpose, safety, adherence, access, and coordination. Confirm whether there have been recent admissions, prescriber changes, new diagnoses, or changes in renal function or other factors only to the extent appropriate to the service and available information. Do not infer a diagnosis or make therapeutic changes beyond authority.

Separate observation from recommendation

Documentation should distinguish a fact from a recommendation. “Patient reports taking the evening dose only twice weekly” is an observation. “Discuss adherence barrier with prescriber and consider a simplified regimen if clinically appropriate” is a recommendation. This distinction protects clarity for the patient, pharmacy team, and care team. It also prevents a care plan from presenting an unconfirmed explanation as a clinical conclusion.

Prioritize problems by patient safety, urgency, patient goal, likelihood of action, and need for a prescriber decision. A long list of low-priority suggestions can obscure the one issue that requires prompt communication. If a concern may require urgent evaluation, follow the pharmacy’s escalation protocol and do not delay action while completing routine MTM documentation.

Document a plan that another person can use

A strong MTM note captures the encounter date, participants, sources reviewed, medication list status, key findings, patient priorities, education provided, recommendations, communication sent, follow-up plan, and unresolved questions. The exact fields should match the payer, program, and pharmacy record requirements. Avoid copying a template paragraph that does not reflect the encounter.

Give the patient an understandable medication action plan when appropriate. Use plain language, specify the next step, and identify who is responsible. If the plan says “contact prescriber,” state whether the pharmacy will send a message, the patient will call, or both. The patient should not leave with a recommendation that has no path to action.

Communication to a prescriber or care team should be concise and actionable. State the relevant medication issue, the supporting observation, the patient impact, and the requested decision or information. Include only the information needed for the purpose and use an approved communication channel. Track whether a response is needed and who will follow up.

Design follow-up before the first appointment

Many medication-related problems cannot be resolved during one conversation. The pharmacy needs a follow-up queue with a named owner, due date, patient-contact method, care-team status, and closure field. Typical follow-up may involve a prescriber response, a refill synchronization question, a coverage issue, a laboratory or monitoring question directed to the appropriate clinician, or confirmation that the patient understands a new instruction.

Do not count an outbound message as resolution. Close the task when the needed action is documented, the patient has been appropriately informed, or the issue has been escalated to the appropriate setting. If the pharmacy cannot reach the patient, follow its established outreach and documentation policy; do not leave an unresolved patient-safety concern only in a general callback list.

Prepare the record before the encounter

Preparation time is a quality control, not clerical waste. Reconcile available dispensing history, identify products that may be obtained elsewhere, list recent changes that need confirmation, and flag questions rather than converting incomplete data into a conclusion. The pharmacist can then spend the patient conversation on understanding use, barriers, and priorities. If the record is incomplete, say so and create a plan to obtain the missing information.

Use a pre-visit script that is respectful of patient choice. Confirm who may participate, whether the patient wants a caregiver included, and whether there are immediate questions that need a different route. A patient may decline a review, need a different appointment time, or prefer a concise conversation. Document the outcome without treating nonparticipation as nonadherence.

Address access barriers without overpromising

Access problems can include price, coverage changes, supply, transportation, delivery limitations, complex refill timing, and difficulty navigating prescriber offices. The MTM workflow can identify and document these barriers, help the patient understand the next step, and coordinate with the appropriate party. It should not promise that a particular formulary exception, assistance program, or alternative medicine will be approved. Explain what the pharmacy can check, who makes the decision, and when the patient should expect an update.

For patients taking many medicines, distinguish a medication problem from a systems problem. A missed refill may result from cost, a hospitalization, a packaging issue, a misunderstanding, or a care-transition gap. Asking an open question first can prevent a workflow from labeling the patient as the cause when the barrier lies elsewhere.

Build a reliable post-encounter handoff

After the encounter, the pharmacist or designated team member should complete the agreed actions while the context is current. Send the care-team message through the approved channel, create the follow-up task, update the patient-facing plan as appropriate, and identify the next contact date. If a recommendation cannot be transmitted immediately, record why and who owns the next attempt. This avoids a common failure mode in which a thoughtful review produces a recommendation that remains in a note.

At the next huddle, review only overdue or patient-impacting MTM tasks. A brief escalation review is more useful than a large list with no priority. For recurring problems, evaluate whether the referral criteria, appointment preparation, documentation template, or communication path needs revision.

Audit for completeness and patient understanding

Periodically review a small sample of encounters for required elements and real-world usability. Did the note reflect what the patient was taking? Was the recommendation linked to evidence in the encounter? Was the communication sent? Was follow-up closed? Could a different pharmacist understand the plan without reconstructing the visit? Use findings to improve the template and training, not simply to create a compliance score.

Patient understanding is also a quality outcome. Ask the patient to describe the next step in their own words when appropriate, and correct misunderstandings before the encounter ends. Written plans should use readable language and avoid unexplained abbreviations. If the patient needs education outside the pharmacy’s capacity, connect them to the appropriate clinician or resource.

Keep program reports separate from care decisions

Payer or program reporting can be necessary, but it should not dictate the clinical conversation. Complete required fields accurately, retain supporting documentation, and use the program’s current rules for submission. At the same time, avoid allowing a checkbox list to replace the patient’s actual question or concern. The patient plan should remain understandable even when the underlying record uses technical coding or program terminology.

When a claim is denied, preserve the relevant submission information and determine whether the issue is eligibility, enrollment, documentation, timing, coding, or a payer-specific rule. Do not edit the clinical record solely to make it appear to match a billing expectation. Correct a genuine documentation error through the pharmacy’s established amendment process, and keep the clinical facts distinct from the billing review.

Set boundaries for remote delivery

Remote MTM can improve access for some patients, but it needs the same preparation, privacy, identity-confirmation, documentation, and escalation standards as an in-person service. Test the patient’s ability to participate safely, offer an alternative when technology is a barrier, and identify when an in-person or prescriber visit is more appropriate. Do not assume a video connection alone makes every clinical service suitable for remote delivery.

Use approved technology and protect the conversation from avoidable disclosure. The pharmacy should know what it will do if a connection fails during a clinically significant discussion, if a caregiver joins, or if an urgent concern is identified. Those decisions belong in the operating protocol before the first remote appointment.

MTM workflow checklist

1. Verify the program, eligibility, and patient cost information.
2. Prepare a preliminary medication record and identify missing sources.
3. Confirm what the patient is actually taking and what matters most to them.
4. Prioritize safety, access, adherence, and coordination issues.
5. Document observations separately from recommendations.
6. Use an approved channel for care-team communication.
7. Assign every follow-up item to a named owner and date.
8. Review closed and reopened cases to improve the process.

Frequently asked questions

Does every patient with several medicines qualify for Medicare Part D MTM?

No. Eligibility is determined under the applicable plan program. Confirm current plan information rather than inferring eligibility from medicine count alone.

Can a pharmacy modify a patient’s therapy during an MTM visit?

Authority depends on state law, collaborative arrangements, protocols, and the specific action. When a prescriber decision is needed, document and communicate the recommendation through the appropriate route.

What is the most important MTM follow-up measure?

A practical starting measure is the share of clinically significant action items that are closed, escalated, or have a documented patient and care-team outcome by the intended deadline.

Conclusion

MTM works when it is a closed-loop service, not a one-time medication list exercise. Confirm eligibility, make the review useful, document responsibility, and follow through on the next action. For service-line planning, see Dispense Times’ community pharmacy clinical-services guide.

References

1. Centers for Medicare & Medicaid Services. Medication Therapy Management. Accessed July 19, 2026.
2. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual. Accessed July 19, 2026.
3. Agency for Healthcare Research and Quality. Pharmacy Patient Safety. Accessed July 19, 2026.